Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
Bulios Fair Price
$11.38
6.2% upside
Current Price
$10.72
According to Bulios Fair Price, TNXP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company focused on developing drugs for the treatment of psychiatric and neurological disorders. Their main product candidates include medicines for the treatment of post-traumatic stress disorder (PTSD), fibromyalgia, and migraines. Tonix Pharmaceuticals focuses on utilizing advanced biotechnological methods and clinical trials to discover new treatment options for patients suffering from these conditions. The company is active in research and development and conducts clinical trials to assess the efficacy and safety of its medicinal products. Tonix Pharmaceuticals Holding Corp. (TNXP) shares could be suitable for investors looking for opportunities in the biopharmaceutical sector with a focus on the treatment of psychiatric and neurological disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Seth Lederman
Employees
142
Headquarters
Berkeley Heights
Upcoming events
Earnings
Upcoming earnings report